Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 11 studies | 62% ± 20% | |
neuron | 9 studies | 66% ± 21% | |
GABAergic neuron | 9 studies | 53% ± 18% | |
retinal ganglion cell | 8 studies | 77% ± 26% | |
oligodendrocyte | 8 studies | 25% ± 9% | |
oligodendrocyte precursor cell | 8 studies | 29% ± 10% | |
endothelial cell | 7 studies | 33% ± 16% | |
astrocyte | 7 studies | 27% ± 13% | |
kidney loop of Henle epithelial cell | 6 studies | 33% ± 8% | |
microglial cell | 6 studies | 21% ± 3% | |
interneuron | 6 studies | 64% ± 16% | |
mesothelial cell | 5 studies | 45% ± 17% | |
pancreatic A cell | 4 studies | 39% ± 12% | |
type B pancreatic cell | 4 studies | 85% ± 12% | |
connective tissue cell | 4 studies | 32% ± 8% | |
abnormal cell | 4 studies | 31% ± 16% | |
amacrine cell | 4 studies | 49% ± 22% | |
retina horizontal cell | 4 studies | 57% ± 17% | |
pancreatic D cell | 3 studies | 85% ± 18% | |
fibroblast | 3 studies | 34% ± 5% | |
kidney distal convoluted tubule epithelial cell | 3 studies | 36% ± 7% | |
GABAergic interneuron | 3 studies | 35% ± 11% | |
granule cell | 3 studies | 24% ± 7% | |
OFF-bipolar cell | 3 studies | 60% ± 30% | |
ON-bipolar cell | 3 studies | 57% ± 32% | |
GABAergic amacrine cell | 3 studies | 46% ± 9% | |
retinal cone cell | 3 studies | 47% ± 20% | |
retinal rod cell | 3 studies | 40% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 32820.41 | 2620 / 2642 | 99% | 381.34 | 696 / 705 |
ovary | 72% | 2536.49 | 129 / 180 | 68% | 164.47 | 293 / 430 |
adrenal gland | 39% | 2330.42 | 100 / 258 | 70% | 727.26 | 162 / 230 |
kidney | 67% | 3026.08 | 60 / 89 | 30% | 62.59 | 266 / 901 |
bladder | 52% | 1990.24 | 11 / 21 | 18% | 50.90 | 90 / 504 |
blood vessel | 62% | 2245.70 | 826 / 1335 | 0% | 0 | 0 / 0 |
intestine | 52% | 2195.03 | 507 / 966 | 7% | 10.14 | 35 / 527 |
lung | 4% | 123.14 | 25 / 578 | 46% | 145.40 | 528 / 1155 |
uterus | 12% | 357.83 | 20 / 170 | 36% | 102.27 | 163 / 459 |
esophagus | 14% | 438.37 | 206 / 1445 | 33% | 98.69 | 60 / 183 |
adipose | 41% | 1499.72 | 498 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 1% | 30.25 | 3 / 328 | 40% | 41.74 | 71 / 178 |
eye | 0% | 0 | 0 / 0 | 40% | 45.74 | 32 / 80 |
skin | 21% | 1216.23 | 387 / 1809 | 17% | 34.73 | 79 / 472 |
tonsil | 0% | 0 | 0 / 0 | 36% | 60.20 | 16 / 45 |
lymph node | 0% | 0 | 0 / 0 | 34% | 43.87 | 10 / 29 |
breast | 17% | 622.49 | 78 / 459 | 13% | 20.43 | 140 / 1118 |
stomach | 17% | 580.61 | 60 / 359 | 8% | 4.68 | 22 / 286 |
muscle | 16% | 583.83 | 131 / 803 | 0% | 0 | 0 / 0 |
prostate | 12% | 406.58 | 30 / 245 | 4% | 3.73 | 20 / 502 |
thymus | 10% | 338.12 | 66 / 653 | 6% | 6.85 | 36 / 605 |
heart | 15% | 471.79 | 130 / 861 | 0% | 0 | 0 / 0 |
liver | 1% | 40.65 | 2 / 226 | 8% | 19.57 | 33 / 406 |
peripheral blood | 5% | 285.73 | 49 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007628 | Biological process | adult walking behavior |
GO_0071466 | Biological process | cellular response to xenobiotic stimulus |
GO_0002176 | Biological process | male germ cell proliferation |
GO_0002931 | Biological process | response to ischemia |
GO_0055001 | Biological process | muscle cell development |
GO_0050905 | Biological process | neuromuscular process |
GO_0042755 | Biological process | eating behavior |
GO_0007412 | Biological process | axon target recognition |
GO_0016579 | Biological process | protein deubiquitination |
GO_0043407 | Biological process | negative regulation of MAP kinase activity |
GO_0016241 | Biological process | regulation of macroautophagy |
GO_0019896 | Biological process | axonal transport of mitochondrion |
GO_0045821 | Biological process | positive regulation of glycolytic process |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_1904115 | Cellular component | axon cytoplasm |
GO_0005886 | Cellular component | plasma membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0043025 | Cellular component | neuronal cell body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0044306 | Cellular component | neuron projection terminus |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0031694 | Molecular function | alpha-2A adrenergic receptor binding |
GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
GO_0008242 | Molecular function | omega peptidase activity |
Gene name | UCHL1 |
Protein name | Ubiquitin C-terminal hydrolase L1 Ubiquitin carboxyl-terminal hydrolase (EC 3.4.19.12) Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1) (EC 3.4.19.12) (Neuron cytoplasmic protein 9.5) (PGP 9.5) (PGP9.5) (Ubiquitin thioesterase L1) |
Synonyms | hCG_33087 |
Description | FUNCTION: Deubiquitinase that plays a role in the regulation of several processes such as maintenance of synaptic function, cardiac function, inflammatory response or osteoclastogenesis . Abrogates the ubiquitination of multiple proteins including WWTR1/TAZ, EGFR, HIF1A and beta-site amyloid precursor protein cleaving enzyme 1/BACE1 . In addition, recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin to maintain a stable pool of monoubiquitin that is a key requirement for the ubiquitin-proteasome and the autophagy-lysosome pathways . Regulates amyloid precursor protein/APP processing by promoting BACE1 degradation resulting in decreased amyloid beta production . Plays a role in the immune response by regulating the ability of MHC I molecules to reach cross-presentation compartments competent for generating Ag-MHC I complexes (By similarity). Mediates the 'Lys-48'-linked deubiquitination of the transcriptional coactivator WWTR1/TAZ leading to its stabilization and inhibition of osteoclastogenesis (By similarity). Deubiquitinates and stabilizes epidermal growth factor receptor EGFR to prevent its degradation and to activate its downstream mediators (By similarity). Modulates oxidative activity in skeletal muscle by regulating key mitochondrial oxidative proteins (By similarity). Enhances the activity of hypoxia-inducible factor 1-alpha/HIF1A by abrogateing its VHL E3 ligase-mediated ubiquitination and consequently inhibiting its degradation . . |
Accessions | D6RF53 ENST00000505232.5 D6RE83 ENST00000514924.5 ENST00000512419.5 ENST00000503431.5 D6RJD9 ENST00000284440.9 ENST00000512788.1 A6NLJ7 ENST00000508768.5 D6R956 D6R974 P09936 |